Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

NCT04660097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER_GOV

Sponsor class

Conditions

SCLC, Extensive Stage

Interventions

DRUG: Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Sponsor

Henan Cancer Hospital